Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BPMC Stock Forecast 2025-2026
$100.34
Current Price
$6.51B
Market Cap
Buy 15
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to BPMC Price Targets
+66.4%
To High Target of $167.00
+29.6%
To Median Target of $130.00
-17.3%
To Low Target of $83.00
BPMC Price Momentum
-1.3%
1 Week Change
+16.9%
1 Month Change
-2.0%
1 Year Change
+15.0%
Year-to-Date Change
-17.7%
From 52W High of $121.90
+37.4%
From 52W Low of $73.04
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Blueprint Medicines (BPMC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BPMC and similar high-potential opportunities.
Latest BPMC Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, BPMC has a bullish consensus with a median price target of $130.00 (ranging from $83.00 to $167.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $100.34, the median forecast implies a 29.6% upside. This outlook is supported by 15 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BPMC Analyst Ratings
15
Buy
5
Hold
1
Sell
BPMC Price Target Range
Low
$83.00
Average
$130.00
High
$167.00
Current: $100.34
Latest BPMC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BPMC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
| Apr 28, 2025 | Needham | Ami Fadia | Buy | Maintains | $130.00 |
| Apr 16, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $128.00 |
| Apr 8, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
| Mar 20, 2025 | Morgan Stanley | Judah Frommer | Equal-Weight | Assumes | $100.00 |
| Mar 17, 2025 | Jefferies | Michael Yee | Buy | Initiates | $135.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $150.00 |
| Mar 3, 2025 | Citizens Capital Markets | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
| Feb 14, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
| Feb 14, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
| Feb 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
| Feb 4, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $129.00 |
| Jan 27, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $119.00 |
| Jan 15, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
| Jan 13, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $124.00 |
| Jan 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $135.00 |
| Jan 2, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
| Dec 17, 2024 | Needham | Buy | Reiterates | $0.00 | |
| Dec 11, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $0.00 |
Blueprint Medicines Corp. (BPMC) Competitors
The following stocks are similar to Blueprint Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BPMC
Blueprint Medicines
mkt cap
6.43B
Blueprint Medicines Corp. (BPMC) Financial Data
Blueprint Medicines Corp. has a market capitalization of $6.51B with a P/E ratio of -93.7x. The company generates $562.12M in trailing twelve-month revenue with a -27.7% profit margin.
Revenue growth is +55.5% quarter-over-quarter, while maintaining an operating margin of -27.5% and return on equity of -47.7%.
Valuation Metrics
Market Cap
$6.51B
Enterprise Value
$6.69B
P/E Ratio
-93.7x
PEG Ratio
-107.3x
Price/Sales
11.6x
Growth & Margins
Revenue Growth (YoY)
+55.5%
Gross Margin
+98.1%
Operating Margin
-27.5%
Net Margin
-27.7%
EPS Growth
-99.4%
Financial Health
Cash/Price Ratio
+8.9%
Current Ratio
2.8x
Debt/Equity
208.5x
ROE
-47.7%
ROA
-9.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Blueprint Medicines Corp. (BPMC) Business Model
About Blueprint Medicines Corp.
What They Do
Develops targeted therapies for cancers and rare diseases.
Business Model
Blueprint Medicines Corp. generates revenue through the development and commercialization of targeted therapies aimed at genomically defined cancers and rare diseases. By leveraging its proprietary scientific platform, the company focuses on creating innovative treatments that specifically inhibit protein kinases associated with disease progression, thereby addressing significant unmet medical needs in oncology and hematology.
Additional Information
Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the use of genomics and data science in its research and development efforts. The company has a diverse pipeline of drug candidates that target conditions such as systemic mastocytosis and advanced thyroid cancers, making it an attractive investment opportunity in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
682
CEO
Ms. Kathryn Haviland M.B.A.
Country
United States
IPO Year
2015
Website
www.blueprintmedicines.comBlueprint Medicines Corp. (BPMC) Latest News & Analysis
Latest News
Quick Summary
VantAI has expanded its collaboration with Blueprint Medicines to include more drug target programs, enhancing their partnership in developing novel therapies for critical medical needs.
Why It Matters
The expanded collaboration between VantAI and Blueprint Medicines signals growth potential and innovation in biotech, which could enhance their market positions and attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
BMPC's Q1 earnings and sales fell short of estimates, yet shares rose due to increased Ayvakit sales guidance for 2025.
Why It Matters
BMPC's earnings miss suggests operational challenges, but the raised Ayvakit sales guidance indicates future growth potential, driving share price optimism despite current underperformance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Blueprint Medicines Corporation (NASDAQ:BPMC) will hold its Q1 2025 earnings conference call on May 1, 2025, at 8:00 AM ET with key executives and analysts participating.
Why It Matters
The earnings call provides insights into Blueprint Medicines' financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Blueprint Medicines reported $149.4 million in AYVAKIT net revenues for Q1 2025, marking 61% growth, and raised its 2025 revenue guidance to $700-$720 million. They also initiated studies for BLU-808.
Why It Matters
Strong revenue growth and raised guidance for AYVAKIT signal robust demand, while new studies on BLU-808 may diversify revenue streams, enhancing Blueprint Medicines' market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Blueprint Medicines (BPMC) reported a quarterly loss of $0.74 per share, worse than the expected loss of $0.42, but an improvement from a loss of $1.32 per share a year earlier.
Why It Matters
Blueprint Medicines' larger-than-expected quarterly loss signals potential operational challenges, impacting investor confidence and future performance outlook.
Source: Zacks Investment Research
Market Sentiment:
Negative
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
27 days ago
Quick Summary
Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on April 25, 2025, at 8:00 a.m.
Why It Matters
Blueprint Medicines' conference call may provide insights into financial performance, strategic initiatives, or product developments, impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BPMC Stock
What is Blueprint Medicines Corp.'s (BPMC) stock forecast for 2025?
Based on our analysis of 32 Wall Street analysts, Blueprint Medicines Corp. (BPMC) has a median price target of $130.00. The highest price target is $167.00 and the lowest is $83.00.
Is BPMC stock a good investment in 2025?
According to current analyst ratings, BPMC has 15 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $100.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BPMC stock?
Wall Street analysts predict BPMC stock could reach $130.00 in the next 12 months. This represents a 29.6% increase from the current price of $100.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Blueprint Medicines Corp.'s business model?
Blueprint Medicines Corp. generates revenue through the development and commercialization of targeted therapies aimed at genomically defined cancers and rare diseases. By leveraging its proprietary scientific platform, the company focuses on creating innovative treatments that specifically inhibit protein kinases associated with disease progression, thereby addressing significant unmet medical needs in oncology and hematology.
What is the highest forecasted price for BPMC Blueprint Medicines Corp.?
The highest price target for BPMC is $167.00 from at , which represents a 66.4% increase from the current price of $100.34.
What is the lowest forecasted price for BPMC Blueprint Medicines Corp.?
The lowest price target for BPMC is $83.00 from at , which represents a -17.3% decrease from the current price of $100.34.
What is the overall BPMC consensus from analysts for Blueprint Medicines Corp.?
The overall analyst consensus for BPMC is bullish. Out of 32 Wall Street analysts, 15 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $130.00.
How accurate are BPMC stock price projections?
Stock price projections, including those for Blueprint Medicines Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:22 AM UTC